Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

“During the summer, we teach Buddhist philosophy. In winter, they learn how to make ritual cakes, blow trumpets, and perform rituals. Since we are in the village, we need to participate in rituals ...